与儿童皮下过敏原免疫疗法相关的风险因素和策略
相关实验视频
Updated: Jan 12, 2026

10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.8K
Lu Qin1, Na Ling2, Jin-Ling Liu1
1Department of Pulmonology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China; Zhejiang Key Laboratory of Neonatal Diseases, Hangzhou, 310052, China.
Respiratory medicine
|November 6, 2025
概括
家庭灰尘子皮下免疫疗法 (SCIT) 对儿童来说是安全的. 患有多种过敏的年轻女孩可能会出现更严重的反应,需要仔细调整剂量.
科学领域:
- 儿科过敏和免疫学
- 免疫治疗的安全性
- 在过敏治疗中的真实世界证据
背景情况:
- 皮下免疫疗法 (SCIT) 是对过敏疾病的关键治疗方法.
- 在接受SCIT的儿科患者群体中,关于全身不良反应 (SRs) 的数据有限.
- 这项研究侧重于东中国儿童的家用灰尘SCIT (HDM-SCIT).
研究的目的:
- 评估在接受HDM-SCIT的儿童中SRs的患病率和严重程度.
- 在这个儿科队列中确定与SRs相关的风险因素.
- 评估HDM-SCIT在儿童中的安全性和耐受性.
主要方法:
- 对427名接受HDM-SCIT的儿童 (5-16岁) 的数据进行分析.
- 检查SR发生,时间,管理和影响因素.
- 调查与人口,临床和治疗变量的关联.
主要成果:
- 在5.60%的注射中发生了SR,主要是轻度至中度.
- 年龄较小的儿童 (5-7岁) 患病率较高.
- 女性性别,年龄较小和多种过敏疾病被确定为SRs的重要危险因素.
结论:
- 对于儿童来说,HDM-SCIT是一种安全且耐受良好的治疗方法.
- 关键的SRs风险因素包括年龄,性别,过敏性疾病的多重性和治疗参数.
- 患有多种过敏的年轻女性儿童需要更密切的监测和量身定制的剂量管理.
相关概念视频
Hypersensitivities
7.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.2K
Allergic Reactions
31.9K
Overview
31.9K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Cross-reactivity
32.8K
Overview
32.8K

